Activity ID



April 26, 2023

Format Type


CME Credit




CME Provider: Potomac Center for Medical Education

Description of CME Course

Approximately one-third of patients with atopic dermatitis (AD) have severe disease that requires systemic treatment directed at controlling immune responses. In recent years, novel therapies targeting the underlying pathophysiology of AD have been approved with many more emerging, but many clinicians lack familiarity with these new and emerging agents as well as related mechanisms of action and safety and efficacy profiles. Furthermore, clinicians often underestimate AD disease severity and the impact on patient’s quality of life (QoL), leading to undertreatment.

This activity “A Bright Horizon: Staying Up To Date with New and Emerging Therapies For Atopic Dermatitis” aims to provide allergists and dermatologists with up-to-date information on management of moderate to severe AD, including the health burden of uncontrolled disease, identification of patients with more severe disease who require treatment escalation, evidence-based use of newer targeted therapies, and how emerging therapies may impact AD management in the near term.

Register for this Activity

ABMS Member Board Approvals by Type
More Information
Commercial Support?

NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.

Educational Objectives

-Discuss type 2 inflammatory processes and related physiologic pathways underlying atopic dermatitis pathophysiology
-Identify patients with moderate to severe atopic dermatitis using evidence-based assessment tools
-Individualize atopic dermatitis action plans based on the goals and needs of the patient using a shared decision-making approach
-Evaluate the safety and efficacy of current and emerging targeted therapies for moderate to severe atopic dermatitis


Atopic dermatitis, Emerging Therapies, JAK inhibitors, Anti-interleukins, Disease Severity Assessment


Interpersonal & Communication Skills, Medical Knowledge, Patient Care & Procedural Skills, Practice-based Learning & Improvement

CME Credit Type

AMA PRA Category 1 Credit

Practice Setting

Outpatient, Rural, Urban

View All Activities by this CME Provider

The information provided on this page is subject to change. Please refer to the CME Provider’s website to confirm the most current information.